- Home
- TSAT vs ATAI Comparison
TSAT vs ATAI Comparison
Compare TSAT & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSAT
- ATAI
- Stock Information
- Founded
- TSAT 1969
- ATAI 2018
- Country
- TSAT Canada
- ATAI Germany
- Employees
- TSAT N/A
- ATAI N/A
- Industry
- TSAT Metal Fabrications
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- TSAT Industrials
- ATAI Health Care
- Exchange
- TSAT Nasdaq
- ATAI Nasdaq
- Market Cap
- TSAT 236.1M
- ATAI 222.3M
- IPO Year
- TSAT 1996
- ATAI 2021
- Fundamental
- Price
- TSAT $17.45
- ATAI $1.50
- Analyst Decision
- TSAT Hold
- ATAI Strong Buy
- Analyst Count
- TSAT 1
- ATAI 4
- Target Price
- TSAT $9.00
- ATAI $9.00
- AVG Volume (30 Days)
- TSAT 52.0K
- ATAI 1.9M
- Earning Date
- TSAT 11-14-2024
- ATAI 11-13-2024
- Dividend Yield
- TSAT N/A
- ATAI N/A
- EPS Growth
- TSAT N/A
- ATAI N/A
- EPS
- TSAT 2.55
- ATAI N/A
- Revenue
- TSAT $450,756,875.00
- ATAI $331,000.00
- Revenue This Year
- TSAT N/A
- ATAI $80.07
- Revenue Next Year
- TSAT N/A
- ATAI N/A
- P/E Ratio
- TSAT $6.08
- ATAI N/A
- Revenue Growth
- TSAT N/A
- ATAI N/A
- 52 Week Low
- TSAT $6.93
- ATAI $1.03
- 52 Week High
- TSAT $19.37
- ATAI $2.85
- Technical
- Relative Strength Index (RSI)
- TSAT 57.48
- ATAI 52.34
- Support Level
- TSAT $14.31
- ATAI $1.36
- Resistance Level
- TSAT $19.37
- ATAI $1.50
- Average True Range (ATR)
- TSAT 1.18
- ATAI 0.15
- MACD
- TSAT -0.17
- ATAI -0.00
- Stochastic Oscillator
- TSAT 62.06
- ATAI 41.43
About TSAT Telesat Corporation and Class B Variable Voting Shares
Telesat Corp is a global satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.